Want to see ASMB full AI Analyst Report?
Total Valuation
Assembly Biosciences has a market cap or net worth of $549.73M. The enterprise value is $355.18M.
Market Cap$549.73M
Enterprise Value$355.18M
Share Statistics
Assembly Biosciences has 19,817,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,817,250
Owned by Insiders27.13%
Owned by Institutions51.46%
Financial Efficiency
Assembly Biosciences’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is -5.79%.
Return on Equity (ROE)-0.03
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)-5.79%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee990.45K
Profits Per Employee-83.86K
Employee Count73
Asset Turnover0.28
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Assembly Biosciences is ―. Assembly Biosciences’s PEG ratio is 0.67.
PE Ratio―
PS Ratio5.27
PB Ratio1.84
Price to Fair Value1.84
Price to FCF-9.26
Price to Operating Cash Flow-11.79
PEG Ratio0.67
Income Statement
In the last 12 months, Assembly Biosciences had revenue of 72.30M and earned -6.12M in profits. Earnings per share was -0.55.
Revenue72.30M
Gross Profit72.17M
Operating Income-12.12M
Pretax Income-6.12M
Net Income-6.12M
EBITDA-5.99M
Earnings Per Share (EPS)-0.55
Cash Flow
In the last 12 months, operating cash flow was -39.75M and capital expenditures -85.00K, giving a free cash flow of -39.84M billion.
Operating Cash Flow-39.75M
Free Cash Flow-39.84M
Free Cash Flow per Share-2.01
Dividends & Yields
Assembly Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.29
52-Week Price Change52.92%
50-Day Moving Average26.73
200-Day Moving Average29.04
Relative Strength Index (RSI)58.60
Average Volume (3m)164.41K
Important Dates
Assembly Biosciences upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Assembly Biosciences as a current ratio of 5.22, with Debt / Equity ratio of 1.25%
Current Ratio5.22
Quick Ratio5.22
Debt to Market Cap0.00
Net Debt to EBITDA9.31
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Assembly Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Assembly Biosciences EV to EBITDA ratio is -54.31, with an EV/FCF ratio of -7.91.
EV to Sales4.50
EV to EBITDA-54.31
EV to Free Cash Flow-7.91
EV to Operating Cash Flow-7.92
Balance Sheet
Assembly Biosciences has $226.60M in cash and marketable securities with $2.49M in debt, giving a net cash position of $224.11M billion.
Cash & Marketable Securities$226.60M
Total Debt$2.49M
Net Cash$224.11M
Net Cash Per Share$11.31
Tangible Book Value Per Share$18.44
Margins
Gross margin is 77.24%, with operating margin of -16.76%, and net profit margin of -8.47%.
Gross Margin77.24%
Operating Margin-16.76%
Pretax Margin-8.47%
Net Profit Margin-8.47%
EBITDA Margin-8.29%
EBIT Margin-8.47%
Analyst Forecast
The average price target for Assembly Biosciences is $46.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$46.00
Price Target Upside57.32% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast121.11%
EPS Growth Forecast80.74%